Eagle Health Investments LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001842545

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q2 2026 · 27 positions · Total reported value $603.31M · Top-10 concentration 66.1% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 54.8% · 4 new · 4 cut · 9 exited

Active Share (vs S&P 500): 99.7% · vs QQQ: 99.4% — share of the book that differs from index weights (higher = more active) · ranking

In its Q2 2026 13F filing, Eagle Health Investments LP disclosed 27 equity positions with a combined reported value of $603.31M. The filing implies a focused portfolio: its ten largest positions account for 66.1% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2026 were ARGX ($70.90M), ICLR ($53.53M), GH ($45.11M). By sector, the heaviest allocations are Health Care 96.0%, Technology 2.5%. Versus the prior quarter, allocation shifted toward Health Care (+21.3pp) and away from Other (-21.7pp).

Versus the prior quarter, Eagle Health Investments LP opened 4 new positions, trimmed 4 and fully exited 9, a turnover rate of 54.8% of positions. The portfolio's overlap with the prior quarter was 69% of names.

The largest new positions opened in Q2 2026 were AXSM ($15.92M), IONS ($15.43M), DNTH ($12.80M).

Of the 9 positions fully exited versus the prior quarter, the largest were XBI ($93.24M), TERN ($21.75M), BBIO ($19.83M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

  • AXSM AXSOME THERAPEUTICS INC. · $15.92M
  • IONS IONIS PHARMACEUTICALS INC · $15.43M
  • DNTH DIANTHUS THERAPEUTICS INC · $12.80M
  • AVTX AVALO THERAPEUTICS INC · $4.34M
  • LLY ELI LILLY & CO · $2.39M

Fully Exited (vs previous quarter)

  • XBI SPDR SERIES TRUST · prev qtr: $93.24M
  • TERN TERNS PHARMACEUTICALS INC · prev qtr: $21.75M
  • BBIO BRIDGEBIO PHARMA INC · prev qtr: $19.83M
  • CNTA CENTESSA PHARMACEUTICALS PLC · prev qtr: $8.51M
  • PRCT PROCEPT BIOROBOTICS CORP · prev qtr: $2.25M

Insider Transactions (Form 4)

Latest Eagle Health Investments LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Eagle Health Investments LP, based in Greenwich, CT, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 27 positions worth $603.31M in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: GREENWICH, CT, United States
  • SEC registration: 801-121917 (status: Approved), registered 2021-07-29
  • Regulatory AUM (Form ADV): $605.26M as of 2026-03-28
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 1 private funds, of which 1 hedge funds

Portfolio Structure

  • 27 positions · $603.31M reported value (Q2 2026)
  • Top 10 holdings = 66.1% of reported value
  • Largest position: ARGX (ARGENX SE FUNSPONSORED ADR 1 ADR REPS 1 ORD SHS) at 11.8%
  • Average position size: $22.34M

Sector Tilt

  • Health Care 96.0%
  • Information Technology 2.5%
  • (classified holdings cover 98% of value)

Quarterly Activity

  • Q2 2026: 5 new, 9 added, 4 reduced, 5 exited
  • 9 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: The Eagle Health Investments LP appears to maintain a cautious yet proactive stance. The fund's focus on healthcare indicates a belief in the sector's long-term potential, but the varying actions taken on holdings suggest a balanced approach with a willingness to adjust positions in response to market conditions. 2. Key Moves: - Added: The fund significantly increased its stake in INSMED INC (INSM), BIOMARIN PHARMACEUTICAL INC (BMRN), SCHOLAR ROCK HLDG CORP (SRRK), and PROTAGONIST THERAPEUTICS INC (PTGX). These additions were substantial, with INSM's position increasing by 71.3% and PTGX's by 38.5%. - Reduced: The fund decreased its holdings in ICON PUB LTD CO (ICLR) and GUARDANT HEALTH INC (GH), with ICLR's position declining by 14.0% and GH's by 3.1%. - Hold: The fund maintained positions in ARGENX SE (ARGX), ILLUMINA INC (ILMN), ULTRAGENYX PHARMACEUTICAL IN (RARE), and COMPASS PATHWAYS PLC (CMPS), with no changes in share count. 3. Portfolio Structure: - Passive/Active: The rebalancing logic suggests an active approach, as there are clear additions, reductions, and holds based on strategic decisions rather than passive index tracking. - Sector Bias: The portfolio is heavily biased towards the healthcare sector, which is a significant focus. - Risk Appetite: The fund exhibits a moderate risk appetite, as it is increasing positions in companies that may offer growth potential but also maintains positions in more established companies. 4. Per-Holding One-Liner: - ARGX: Argenx SE is a biopharmaceutical company specializing in the development and commercialization of therapies for rare and serious diseases. - ICLR: ICON Public Limited Company is a global provider of clinical development solutions to the pharmaceutical, biotechnology, and medical device industries. - GH: Guardant Health Inc. is a molecular diagnostics company focused on improving treatment for cancer patients through the use of circulating tumor DNA (ctDNA) sequencing. - INSM: InSMED Inc. is a biotechnology company focused on the development of a next-generation bioresorbable drug delivery system. - BMRN: Biomerica Pharmaceutical Inc. is a biopharmaceutical company that discovers, develops, and commercializes novel small molecule therapeutics. - ILMN: Illumina, Inc. is a company that develops, manufactures, and markets life science tools and integrated systems for genomic sequencing, array-based technologies, and related products. - SRRK: Scholar Rock Holding Corp. is a biopharmaceutical company focused on the development of therapies targeting the SR protein family. - PTGX: Protagonist Therapeutics Inc. is a biopharmaceutical company focused on the development of novel therapies that modulate the body's natural signaling pathways. - RARE: Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on the development of therapies for rare and ultra-rare genetic diseases. - CMPS: Compass Pathways PLC is a biopharmaceutical company that is developing novel approaches to treat mental health disorders. 5. One-Sentence Style Summary: Eagle Health Investments LP maintained a diversified healthcare portfolio with a focus on biotechnology and molecular diagnostics, strategically increasing exposure to potentially high-growth companies while balancing risk with holdings in established players.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 96.0%
Technology 2.5%
Other 1.6%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 76.42K $70.90M 11.75%
11.75%
Hold
2 308.14K $53.53M 8.87%
8.87%
Reduce
3 300.69K $45.11M 7.48%
7.48%
Reduce
4 384.13K $40.96M 6.79%
6.79%
Add
5 624.68K $35.74M 5.92%
5.92%
Add
6 187.41K $32.95M 5.46%
5.46%
Hold
7 555.27K $30.54M 5.06%
5.06%
Add
8 248.32K $30.44M 5.04%
5.04%
Add
9 884.12K $29.52M 4.89%
4.89%
Hold
10 2.06M $29.16M 4.83%
4.83%
Hold
11 106.16K $28.31M 4.69%
4.69%
Add
12 120.35K $22.54M 3.74%
3.74%
Add
13 1.18M $20.55M 3.41%
3.41%
Reduce
14 166.15K $19.05M 3.16%
3.16%
Add
15 65.05K $15.92M 2.64%
2.64%
New
16 369.16K $15.76M 2.61%
2.61%
Add
17 297.30K $15.58M 2.58%
2.58%
Add
18 194.58K $15.43M 2.56%
2.56%
New
19 256.27K $14.85M 2.46%
2.46%
Hold
20 131.34K $12.80M 2.12%
2.12%
New
21 1.71M $9.01M 1.49%
1.49%
Hold
22 235.09K $4.34M 0.72%
0.72%
New
23 15.85K $4.30M 0.71%
0.71%
Reduce
24 1.99K $2.39M 0.40%
0.40%
New
25 4.39K $1.75M 0.29%
0.29%
Hold
26 46.30K $1.47M 0.24%
0.24%
Hold
27 37.69K $410.02K 0.07%
0.07%
Hold

FAQ

What did Eagle Health Investments LP buy in 2026-Q2?

In its 2026-Q2 13F filing, Eagle Health Investments LP reported 27 equity positions worth $603.31M in aggregate; its largest disclosed positions were ARGX ($70.90M), ICLR ($53.53M), GH ($45.11M).

How large is Eagle Health Investments LP's portfolio?

Eagle Health Investments LP reported $603.31M of long equity holdings across 27 positions as of 2026-Q2. Top-10 holdings account for 66.1% of reported value.

What is Eagle Health Investments LP's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/eagle-health-investments/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →